Bryan Giraudo - Gossamer Bio COO CFO
GOSS Stock | USD 1.02 0.05 5.15% |
COO
Mr. Bryan M. Giraudo is Chief Financial Officer of the Company since May 2018. Prior to joining us, Mr. Giraudo was a Senior Managing Director at Leerink Partners from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining Leerink, Mr. Giraudo was a Managing Director in Merrill Lynch, Pierce, Fenner Smith Incorporateds Global Healthcare Investment Banking Group. He was a member of the board of directors of Protagonist Therapeutics, Inc. since May 2018 since 2018.
Age | 50 |
Tenure | 7 years |
Address | 3013 Science Park Road, San Diego, CA, United States, 92121 |
Phone | 858 684 1300 |
Web | https://www.gossamerbio.com |
Bryan Giraudo Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bryan Giraudo against Gossamer Bio stock is an integral part of due diligence when investing in Gossamer Bio. Bryan Giraudo insider activity provides valuable insight into whether Gossamer Bio is net buyers or sellers over its current business cycle. Note, Gossamer Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gossamer Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bryan Giraudo over six months ago Acquisition by Bryan Giraudo of 100000 shares of Gossamer Bio at 0.5911 subject to Rule 16b-3 | ||
Bryan Giraudo over a year ago Purchase by Bryan Giraudo of 200000 shares of Gossamer Bio | ||
Bryan Giraudo over a year ago Acquisition by Bryan Giraudo of 54020 shares of Gossamer Bio subject to Rule 16b-3 | ||
Bryan Giraudo over a year ago Disposition of 150000 shares by Bryan Giraudo of Gossamer Bio subject to Rule 16b-3 |
Gossamer Bio Management Efficiency
The company has return on total asset (ROA) of (0.1124) % which means that it has lost $0.1124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9026) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2025. Return On Capital Employed is likely to gain to -0.77 in 2025. At this time, Gossamer Bio's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 923.7 K in 2025, whereas Total Assets are likely to drop slightly above 293.4 M in 2025.Similar Executives
Found 3 records | COO Age | ||
Deborah Knobelman | Kronos Bio | 51 | |
Matthew Winton | Inozyme Pharma | 47 | |
Seokho Esq | Terns Pharmaceuticals | 46 |
Management Performance
Return On Equity | -0.9 | ||||
Return On Asset | -0.11 |
Gossamer Bio Leadership Team
Elected by the shareholders, the Gossamer Bio's board of directors comprises two types of representatives: Gossamer Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gossamer. The board's role is to monitor Gossamer Bio's management team and ensure that shareholders' interests are well served. Gossamer Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gossamer Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Colin Rowlings, Senior CMC | ||
Robert Smith, Chief Officer | ||
Matt Cravets, Senior Biometrics | ||
Jeff Boerneke, General Secretary | ||
Christian Waage, Executive Vice President General Counsel | ||
Richard MD, Chief Officer | ||
Mario Orlando, Senior Planning | ||
Caryn Peterson, Executive Affairs | ||
Faheem Hasnain, Executive Chairman of the Board, Co-Founder | ||
Laura Carter, Chief Officer | ||
Deanna Weber, Vice President of Human Resources | ||
Christian JD, Executive Administration | ||
Bryan Giraudo, COO CFO | ||
Lisa Nolan, MD Ireland |
Gossamer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gossamer Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.9 | ||||
Return On Asset | -0.11 | ||||
Profit Margin | (0.68) % | ||||
Operating Margin | (3.58) % | ||||
Current Valuation | 107.73 M | ||||
Shares Outstanding | 226.6 M | ||||
Shares Owned By Insiders | 3.29 % | ||||
Shares Owned By Institutions | 78.23 % | ||||
Number Of Shares Shorted | 7.02 M | ||||
Price To Earning | (4.61) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.